{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:12:59Z","timestamp":1780463579235,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["5NU2RGH001913-02-00"],"award-info":[{"award-number":["5NU2RGH001913-02-00"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3074-0","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T14:36:59Z","timestamp":1524148619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9645-7595","authenticated-orcid":false,"given":"Radboud J.","family":"Duintjer Tebbens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"3074_CR1","unstructured":"World Health Organization: Polio eradication initiative. Cessation of routine oral polio vaccine (OPV) use after global polio eradication. Framework for National Policy Makers in OPV-using countries. Report number: WHO\/POL\/05.02. Geneva: World Health Organization; 2005."},{"key":"3074_CR2","unstructured":"World Health Organization: Global polio eradication initiative: polio eradication and endgame strategic plan (2013-2018). Report number: WHO\/POLIO\/13.02. Geneva: World Health Organization; 2013."},{"issue":"6","key":"3074_CR3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1539-6924.2006.00827.x","volume":"26","author":"RJ Duintjer Tebbens","year":"2006","unstructured":"Duintjer Tebbens RJ, Pallansch MA, Kew OM, C\u00e1ceres VM, Jafari H, Cochi SL, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471\u2013505.","journal-title":"Risk Anal"},{"key":"3074_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12879-015-1112-8","volume":"15","author":"RJ Duintjer Tebbens","year":"2015","unstructured":"Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis. 2015;15:389.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"3074_CR5","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/AJPH.2007.122192","volume":"98","author":"KM Thompson","year":"2008","unstructured":"Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE Jr, Alexander JP Jr, Jafari H, et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health. 2008;98(7):1322\u201330.","journal-title":"Am J Public Health"},{"key":"3074_CR6","unstructured":"Global Polio Eradication Initiative; Global eradication of wild poliovirus type 2 declared. \n                    http:\/\/www.polioeradication.org\/mediaroom\/newsstories\/Global-eradication-of-wild-poliovirus-type-2-declared\/tabid\/526\/news\/1289\/Default.aspx\n                    \n                  . Accessed 30 Nov 2015."},{"issue":"35","key":"3074_CR7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","volume":"65","author":"LM Hampton","year":"2016","unstructured":"Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris J, Hyde T, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(35):934\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"52","key":"3074_CR8","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.15585\/mmwr.mm6552a9","volume":"65","author":"S Bahl","year":"2017","unstructured":"Bahl S, Hampton LM, Bhatnagar P, Rao GS, Haldar P, Sangal L, Jetty PA, Nalavade UP. Notes from the field: detection of Sabin-like type 2 poliovirus from sewage after global cessation of trivalent oral poliovirus vaccine - Hyderabad and Ahmedabad, India, August-September 2016. MMWR Morb Mortal Wkly Rep. 2017;65(52):1493\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3074_CR9","doi-asserted-by":"crossref","unstructured":"Farrell M, Hampton LM, Shendale S, et al. Monitoring and validation of the global replacement of tOPV with bOPV, April-May, 2016. J Infect Dis. 2017; (in press)","DOI":"10.1093\/infdis\/jiw558"},{"issue":"45","key":"3074_CR10","first-page":"1031","volume":"63","author":"OM Kew","year":"2014","unstructured":"Kew OM, Cochi SL, Jafari HS, Wassilak SG, Mast EE, Diop OM, Tangermann RH, Armstrong GL. Centers for disease control and prevention (CDC): possible eradication of wild poliovirus type 3--worldwide, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(45):1031\u20133.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3074_CR11","unstructured":"World Health Organization; Polio this week as of 8 February 2017. \n                    http:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/\n                    \n                  . Accessed 11 Feb 2017."},{"issue":"Suppl 1","key":"3074_CR12","doi-asserted-by":"publisher","first-page":"S475","DOI":"10.1093\/infdis\/jit845","volume":"210","author":"KM Thompson","year":"2014","unstructured":"Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210(Suppl 1):S475\u201384.","journal-title":"J Infect Dis"},{"key":"3074_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12879-015-1115-5","volume":"15","author":"RJ Duintjer Tebbens","year":"2015","unstructured":"Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis. 2015;15:379.","journal-title":"BMC Infect Dis"},{"key":"3074_CR14","doi-asserted-by":"crossref","unstructured":"Ramirez Gonzalez A, Farrell M, Menning L, et al. Implementing the synchronized global switch from trivalent to bivalent oral polio vaccines \u2013 lessons learned from the global perspective. J Infect Dis. 2017; (in press)","DOI":"10.1093\/infdis\/jiw626"},{"key":"3074_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12879-016-1537-8","volume":"16","author":"RJ Duintjer Tebbens","year":"2016","unstructured":"Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis. 2016;16:237.","journal-title":"BMC Infect Dis"},{"key":"3074_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12879-016-1536-9","volume":"16","author":"RJ Duintjer Tebbens","year":"2016","unstructured":"Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infect Dis. 2016;16:231.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"3074_CR17","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1539-6924.2012.01864.x","volume":"33","author":"RJ Duintjer Tebbens","year":"2013","unstructured":"Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544\u2013605.","journal-title":"Risk Anal"},{"issue":"4","key":"3074_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/risa.12031","volume":"33","author":"RJ Duintjer Tebbens","year":"2013","unstructured":"Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal. 2013;33(4):606\u201346.","journal-title":"Risk Anal"},{"issue":"15","key":"3074_CR19","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1056\/NEJMoa054960","volume":"356","author":"The Cuba IPV Study Collaborative Group","year":"2007","unstructured":"The Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med. 2007;356(15):1536\u201344.","journal-title":"N Engl J Med"},{"key":"3074_CR20","unstructured":"UNICEF; Inactivated poliovirus vaccine: Supply update - September 2016. \n                    https:\/\/www.unicef.org\/supply\/files\/Inactivated_Polio_Vaccine_(IPV)_-_september_2016.pdf\n                    \n                  . Accessed 14 Feb 2017."},{"key":"3074_CR21","doi-asserted-by":"crossref","unstructured":"Hampton LM, du Ch\u00e2telier GM, Fournier-Caruana J, Ottosen A, Rubin J, Menning L, Farrell M, Shendale S, Patel M. Considerations for the full global withdrawal of oral polio vaccine after eradication of polio. J Infect Dis. 2017; (in press)","DOI":"10.1093\/infdis\/jix105"},{"issue":"4","key":"3074_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/risa.12044","volume":"23","author":"RJ Duintjer Tebbens","year":"2013","unstructured":"Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703\u201349.","journal-title":"Risk Anal"},{"issue":"5","key":"3074_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4172\/2157-7560.1000339","volume":"7","author":"RJ Duintjer Tebbens","year":"2016","unstructured":"Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccin. 2016;7(5):340.","journal-title":"J Vaccines Vaccin"},{"key":"3074_CR24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12879-015-1113-7","volume":"15","author":"KM Thompson","year":"2015","unstructured":"Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis. 2015;15:374.","journal-title":"BMC Infect Dis"},{"key":"3074_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2334-14-45","volume":"14","author":"RJ Duintjer Tebbens","year":"2014","unstructured":"Duintjer Tebbens RJ, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis. 2014;14:45.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"3074_CR26","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/risa.12022","volume":"23","author":"RJ Duintjer Tebbens","year":"2013","unstructured":"Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, Diop O, Wassilak SGF, Cochi SL, Thompson KM. Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013;23(4):680\u2013702.","journal-title":"Risk Anal"},{"key":"3074_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","volume":"16","author":"RJ Duintjer Tebbens","year":"2016","unstructured":"Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis. 2016;16:137.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"3074_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14760584.2017.1322514","volume":"16","author":"RJ Duintjer Tebbens","year":"2017","unstructured":"Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Exp Rev Vaccines. 2017;16(6):577\u201386.","journal-title":"Exp Rev Vaccines"},{"key":"3074_CR29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12879-015-1114-6","volume":"15","author":"RJ Duintjer Tebbens","year":"2015","unstructured":"Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis. 2015;15:390.","journal-title":"BMC Infect Dis"},{"issue":"Suppl 1","key":"3074_CR30","doi-asserted-by":"publisher","first-page":"S398","DOI":"10.1093\/infdis\/jit844","volume":"210","author":"DA Kalkowska","year":"2014","unstructured":"Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis. 2014;210(Suppl 1):S398\u2013411.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"3074_CR31","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","volume":"210","author":"C Burns","year":"2014","unstructured":"Burns C, Diop O, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(Suppl 1):S283\u201393.","journal-title":"J Infect Dis"},{"key":"3074_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","volume":"59","author":"OM Kew","year":"2005","unstructured":"Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587\u2013635.","journal-title":"Annu Rev Microbiol"},{"issue":"25","key":"3074_CR33","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1056\/NEJMoa0910074","volume":"326","author":"HE Jenkins","year":"2010","unstructured":"Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, Garnier S, Chauvin C, Abanida E, Pate MA, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010;326(25):2360\u20139.","journal-title":"N Engl J Med"},{"key":"3074_CR34","volume-title":"Summary of discussions and recommendations, 16th informal consultation of the global polio laboratory network, 22\u201323 September 2010, WHO\/HQ. Report number","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. Summary of discussions and recommendations, 16th informal consultation of the global polio laboratory network, 22\u201323 September 2010, WHO\/HQ. Report number. Geneva: World Health Organization; 2010."},{"issue":"4","key":"3074_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1586\/erv.11.195","volume":"11","author":"KM Thompson","year":"2012","unstructured":"Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Expert Rev Vaccine. 2012;11(4):449\u201359.","journal-title":"Expert Rev Vaccine"},{"key":"3074_CR36","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12879-015-1116-4","volume":"15","author":"KM Thompson","year":"2015","unstructured":"Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis. 2015;15:376.","journal-title":"BMC Infect Dis"},{"key":"3074_CR37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/clinids\/14.2.568","volume":"14","author":"PM Strebel","year":"1992","unstructured":"Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992;14:568\u201379.","journal-title":"Clin Infect Dis"},{"key":"3074_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12879-015-0745-y","volume":"15","author":"HB Wang","year":"2015","unstructured":"Wang HB, Zhang LF, Yu WZ, Wen N, Yan DM, Tang JJ, Zhang Y, Fan CX, Reilly KH, Xu WB, et al. Cross-border collaboration between China and Myanmar for emergency response to imported vaccine derived poliovirus case. BMC Infect Dis. 2015;15:18.","journal-title":"BMC Infect Dis"},{"key":"3074_CR39","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3201\/eid1707.110059","volume":"17","author":"R Piarroux","year":"2011","unstructured":"Piarroux R, Barrais R, Faucher B, Haus R, Piarroux M, Gaudart J, Magloire R, Raoult D. Understanding the cholera epidemic, Haiti. Emerg Infect Dis. 2011;17:1161\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"3074_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1012928","volume":"364","author":"CS Chin","year":"2011","unstructured":"Chin CS, Sorenson J, Harris JB, Robins WP, Charles RC, Jean-Charles RR, Bullard J, Webster DR, Kasarskis A, Peluso P, et al. The origin of the Haitian cholera outbreak strain. N Engl J Med. 2011;364(1):33\u201342.","journal-title":"N Engl J Med"},{"issue":"8","key":"3074_CR41","first-page":"190","volume":"10","author":"KM Thompson","year":"2008","unstructured":"Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J Med. 2008;10(8):190.","journal-title":"Medscape J Med"},{"issue":"3","key":"3074_CR42","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/wber\/lhq018","volume":"24","author":"S Barrett","year":"2010","unstructured":"Barrett S. Stop! The polio vaccination cessation game. World Bank Econ Rev. 2010;24(3):361\u201385.","journal-title":"World Bank Econ Rev"},{"issue":"20","key":"3074_CR43","doi-asserted-by":"publisher","first-page":"538","DOI":"10.15585\/mmwr.mm6620a4","volume":"66","author":"OM Diop","year":"2017","unstructured":"Diop OM, Asghar H, Gavrilin E, Moeletsi NG, Benito GR, Paladin F, Pattamadilok S, Zhang Y, Goel A, Quddus A. Virologic monitoring of poliovirus type 2 after oral poliovirus vaccine type 2 withdrawal in April 2016 - worldwide, 2016-2017. MMWR Morb Mortal Wkly Rep. 2017;66(20):538\u201342.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 1","key":"3074_CR44","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.1093\/infdis\/jit838","volume":"210","author":"RJ Duintjer Tebbens","year":"2014","unstructured":"Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014;210(Suppl 1):S485\u201397.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"3074_CR45","doi-asserted-by":"publisher","first-page":"S412","DOI":"10.1093\/infdis\/jit834","volume":"210","author":"DA Kalkowska","year":"2014","unstructured":"Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of Northwest Nigeria. J Infect Dis. 2014;210(Suppl 1):S412\u201323.","journal-title":"J Infect Dis"},{"key":"3074_CR46","unstructured":"UNICEF; Oral polio vaccine supply outlook - December 2015. \n                    https:\/\/www.unicef.org\/supply\/files\/Oral_Polio_Vaccine_Outlook__December_2015.pdf\n                    \n                  . Accessed 14 Feb 2017."},{"key":"3074_CR47","doi-asserted-by":"crossref","unstructured":"Shirreff G, Wadood MZ, Vaz RG, Sutter RW, Grassly NC: Estimated effect of inactivated poliovirus vaccine campaigns, Nigeria and Pakistan, January 2014-April 2016. Emerg Infect Dis 2017, 23(2):258\u201363.","DOI":"10.3201\/eid2302.161210"},{"issue":"30","key":"3074_CR48","doi-asserted-by":"publisher","first-page":"770","DOI":"10.15585\/mmwr.mm6530a4","volume":"65","author":"A Etsano","year":"2016","unstructured":"Etsano A, Damisa E, Shuaib F, Nganda GW, Enemaku O, Usman S, Adeniji A, Jorba J, Iber J, Ohuabunwo C, et al. Environmental isolation of circulating vaccine-derived poliovirus after interruption of wild poliovirus transmission - Nigeria, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(30):770\u20133.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 1","key":"3074_CR49","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/infdis\/jix128","volume":"216","author":"KM Thompson","year":"2017","unstructured":"Thompson KM, Duintjer Tebbens RJ. Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis. 2017;216(Suppl 1):S168\u201375.","journal-title":"J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3074-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3074-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3074-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T11:27:29Z","timestamp":1589455649000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3074-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3074"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3074-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]},"assertion":[{"value":"10 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"165"}}